AZ looks to pipeline, launches to offset patent cliff

In the company's 2Q16 financial presentation on Thursday, AstraZeneca plc (NYSE:AZN; LSE:AZN) CEO Pascal Soriot stressed pipeline progress and growth from new product launches as the company rebuilds from the loss of key products' patent protection. AZ gained $2.75 to $34.29 in New York and 337p to 5,027p in London on Thursday.

Soriot emphasized upcoming data readouts including the Phase III MYSTIC and ARCTIC trials of durvalumab ( MEDI4736) plus tremelimumab ( CP-675) to treat non-small cell lung cancer (NSCLC), both expected in 1H17. ...